AMR Accelerator’s Post

Uncover insights into #DAPT duration post-flow diverter treatment. Dr. Jildaz CAROFF shares findings from an analysis involving 700 patients, revealing peaks in DAPT length and excellent safety outcomes. Optimize therapeutic strategies based on real-world evidence! https://ow.ly/ozHh50QCLT8

Cope, et al. present their results of their Phase 2b clinical study on the feasibility, efficacy, and acceptability of the use of abatacept to treat individuals with a high risk of developing RA. They found that abatacept reduced the risk of RA development in high-risk patients and was well-tolerated within this population. You can find the full paper summary on the IMID Forum completely free along with the latest updates in #RhematoidArthritis ➡️ https://lnkd.in/dDTXbBkp

🌟Some thoughts on digital therapeutics 🌟 The short article on digital therapeutics prepared with my colleague Lukas summarizing the challanges these new types of interventions for health disorders have to face is out! 🥳 Neither the Slovak nor the EU legislation (maybe the new 🤔) is fully prepared for this type of therapeutic intervention. This is in spite of the fact that these are the type of interventions that provide significant help to patients 😷, often with chronic conditions, facilitate patient management 📝 and, last but not least, preserve public funds 💶 #ments #mentsattorneys #Innovation #HealthcareInnovation

It is so important for HCPs and patients alike (some are both, of course😉), to be aware of the importance of PGx testing! It is a simple saliva test that will be converted into a personalised report telling the patient and their prescriber (relevant for now or in the future) which drugs will match their gene variants associated with drug metabolism. A one off test to receive the information that will be relevant for the rest of your life! At only £399, it’s a small price to pay for the knowledge that could just save your life! See mantara.co for more information. #mantara #personalisedmedicine #pharmacogenomics #pharmacogenetics

Ensuring your voice is heard loud and clear is one of our priorities. Yesterday, Jo Lowe from ASIF, represented people living with #axSpA at a Patient Leader Workshop focused on #biosimilar treatments. The workshop emphasised the breadth of information that people taking biosimilars need to know and understand, as well as the importance of shared decision-making.     Today, Jo will attend the 20th edition of the Biosimilar Medicines Conference in Amsterdam where sessions will cover biosimilar health economy and policy; and seek to find better ways to address some of the challenges in developing of biosimilars.    #axialspondyloarthritis #BIOS24

Hear from our CEO, Rohan Palekar about his perspective on what it will take to reverse fibrosis in patients with advanced metabolic dysfunction-associated steatohepatitis (MASH) in his recent Endpoints News article. Rohan also shares the latest developments in potential treatment options, including our lead treatment candidate for MASH now in Phase 3 clinical trials. Read the full article here: https://lnkd.in/g8V_Gbwy #Innovation #MASH #LiverDisease 

A great first day at the Orphan Drugs & Rare Diseases Global Congress, which has left me with several thoughts ⬇ - Health inequity has long been an issue in rare diseases, but the trend towards personalised medicine may help - Patient groups are breaking down barriers, working with the NHS and forming connected networks to encourage innovation and promote health equity - Science is no longer the limiting factor holding back access to rare disease treatment – the challenge lies in investment and the demonstration of value Patient groups and the pharmaceutical industry are leading the way in the innovative demonstration of value, but are payers and regulators lagging behind and hampering progress? #rarediseases #orphandrugs #healthequity #innovation

Rare diseases impact millions worldwide, yet finding effective treatments remains a significant challenge. 🦓 In our latest webinar, Sano Co-Founder and COO Charlotte Guzzo chats with Dr Harriet Holme MD PhD, Drug Development Clinician at Weatherden and Chair/Founder of PCD Research. They discuss the obstacles standing in the way of progress in rare disease—like long diagnostic delays and regulatory red tape—and explore strategies to overcome them. 🔬 Watch the webinar on-demand now to catch this important conversation👇 https://lnkd.in/edNhajqc #RareDiseases #PrecisionMedicine #ClinicalTrials

Reflecting on recent advancements in clinical trial strategies, it's inspiring to see how data analytics are transforming the way we approach research, especially in rare diseases. By identifying key KOL and high-volume sites across multiple countries, we're enhancing our trial strategy and prioritizing patient safety and efficacy. It's exciting to be part of an era where data-driven insights are shaping the future of healthcare. I'm thrilled to be part of this evolving landscape in drug development. #DataAnalytics #ClinicalTrials #RareDisease #Healthcare #DrugDevelopment #patientsafety #kol

Collaboration is key to advancing global health goals. 80% drop in new cases by 2030 is achievable. Utilizing the African Clinical Scientific community may be #Gatekeeper. Let's Unite efforts for a TB-free world! #TBresearch #GlobalHealth #Collaboration